Ovulation Induction (oi)

Ovulation induction (OI) is fertility treatment with medication. Tablets or injections stimulate the ovaries to develop eggs and release them, for women who do not ovulate regularly or at all (Gloucestershire Hospitals NHS Foundation Trust). It sits at the least invasive end of fertility care: the other two types of fertility treatment are surgical procedures and assisted conception, such as intrauterine insemination (IUI) and in vitro fertilization (IVF) (NHS).

If any of these symptoms appear during or after a cycle, get urgent local medical care now and do not wait for a planned cycle, an appointment, or a flight: rapid weight gain, severe pain or swelling in the belly, shortness of breath, persistent vomiting, decreased urination, or pain, swelling or warmth in one leg (MedlinePlus, Cleveland Clinic). These can be signs of ovarian hyperstimulation syndrome (OHSS) or of a blood clot, and both can worsen (Royal College of Obstetricians and Gynaecologists).

Trying for a baby without success, or being told you do not ovulate regularly, brings more questions than answers at first. This guide walks you through what OI involves, from the fertility assessment to the pregnancy test; who it suits and who it will not help; what the medication can do and what waiting does instead; and how to protect yourself if a cycle happens abroad.

What ovulation induction is

The medicines work by two routes. Clomiphene, known by the brand name Clomid, is the tablet most often prescribed first; letrozole is the other common oral option, and it works by lowering the amount of estrogen the body makes so the ovaries release eggs (NICHD). The two versions of OI are:

  • Oral tablets. Clomiphene is a medication patients take by mouth (NICHD). Clomid Treatment covers the oral family in more detail.
  • Injectable gonadotropins. Hormones such as follicle-stimulating hormone (FSH) are injected to stimulate eggs directly; they are normally prescribed when a woman does not respond to clomiphene, or to stimulate follicle growth for assisted reproduction (NICHD).

OI belongs to Obstetrics and Gynecology. Around it sit the services that make a cycle happen: diagnostics for the hormone and egg-reserve blood tests, radiology for the ultrasound monitoring, the consultation or check-up that starts the work-up, and pathology when sperm is prepared for a combined insemination. The insemination itself is intrauterine insemination (IUI), and when the underlying cause, blocked tubes, fibroids, or endometriosis, needs an operation, that is surgery. Assisted laser hatching is an IVF laboratory technique, not a form of OI.

If OI and insemination do not lead to pregnancy, the more involved options under Fertility Treatment are artificial insemination with donor sperm, ICSI with IMSI, frozen embryo transfer, embryo donation, egg donation, and egg donation with sperm donation; and preserving eggs or embryos for later is egg freezing, egg and ovarian cortex freezing, embryo freezing, or embryo, oocyte and sperm cryopreservation.

How ovulation induction works

A fertility assessment comes first, and it exists to find whether the ovaries are the problem before any medication is tried. A blood test checks the hormone progesterone, which rises after ovulation (NHS). A transvaginal ultrasound, a probe placed in the vagina, examines the womb, ovaries and fallopian tubes (NHS). A hysterosalpingogram is an X-ray of the womb and tubes after a special dye is injected, and it shows blockages (NHS). Egg-reserve tests matter too: high FSH and low antimüllerian hormone (AMH) measured at the start of a period suggest the ovaries are failing, and fertility treatment is less successful in those cases (UHCW).

The decision is made together: the clinic reviews your results, your age and your cause, and explains which drug, at what dose, and why. Consent here means you understand the plan, the monitoring schedule, and what happens if a cycle fails.

The American College of Obstetricians and Gynecologists recommends clomiphene as the primary medication for PCOS-related infertility (NICHD), taken as one tablet a day from day 2 to 6 of the cycle, five days in total (Gloucestershire). Some studies have found letrozole may work better than clomiphene in women with PCOS (NICHD). If tablets do not produce ovulation, gonadotropins come next: self-injections given just under the skin, with the dose set individually for each cycle (Health Canada).

The response to any drug given is monitored with ultrasound scans (UHCW); with gonadotropins the clinic uses transvaginal ultrasound to monitor the size of the developing eggs, alongside blood hormone tests (NICHD). Monitoring is the step that catches an over-response early, and it is the first thing to confirm is properly arranged if a cycle happens abroad.

When follicles reach an appropriate size, intercourse is advised on timing, or an injection of human chorionic gonadotropin (hCG) is given to time ovulation for intercourse or insemination (UHCW). That trigger injection also raises the chance of OHSS (MedlinePlus).

Then comes the two-week wait: ovulation, fertilization, implantation, and a pregnancy test about two weeks after the trigger. A positive test is followed by an early scan to confirm the pregnancy is in the uterus, because OI slightly raises the chance of an ectopic pregnancy (Health Canada).

If it does not work, treatment usually continues for up to 6 cycles when the response is satisfactory (UHCW). If a woman does not become pregnant after taking clomiphene for six menstrual cycles, other fertility treatments are considered (NICHD). For PCOS specifically, if there is no pregnancy within 6 months, couples are usually advised to discuss IUI or IVF (ACOG).

Who it is for, and when not to wait

OI helps most when infertility is due to problems with ovulation, and least when eggs and sperm cannot meet: treatment with medications is least likely to benefit infertility caused by damage to the fallopian tubes or severe endometriosis, although IVF can help those conditions (NICHD).

Polycystic ovary syndrome (PCOS) is the single most common cause of anovulatory infertility, meaning infertility from the absence of ovulation (NICHD). The other common causes of failing to ovulate are stress and weight fluctuations (UHCW). PCOS affects up to 13 in 100 women of reproductive age in the United States, and there is no cure, but women with PCOS do not ovulate regularly and can conceive with help (ACOG).

For unexplained infertility, advice differs by country. In England, ovarian-stimulating medicine is not recommended because it has not been found to increase the chances of getting pregnant (NHS). US researchers have nevertheless studied letrozole in unexplained infertility, finding a live birth in 19% of couples after 4 months, slightly below clomiphene at 23% (NICHD). It is fair to ask which evidence a clinic applies.

OI is also unlikely to be the right path when egg reserve is low (UHCW), when the male factor is severe (the answer there is usually ICSI with IMSI), or when age has narrowed the options; NICE refers women aged 36 and over to a specialist at presentation (NICE).

Waiting is not neutral. More than 8 in 10 couples where the woman is under 40 conceive naturally within a year of regular trying, and about half of the rest conceive in the second year, so a first year without success is normal, not alarming (NHS). But an underlying cause does not resolve on its own. For a woman with PCOS, not ovulating regularly leaves longer-term risks: endometrial hyperplasia, a thickening of the uterine lining, and endometrial cancer, as well as type 2 diabetes or prediabetes, which affects more than one-half of women with PCOS before their early 40s (NICHD). Age works the same way, which is why specialist referral starts at 36 (NICE). Not pursuing treatment is a real and legitimate choice. If you do take it up, the assessment is the first step: see a doctor after a year of trying, and sooner if you are 36 or over, or have any other reason to be concerned, such as prior cancer treatment or a suspected sexually transmitted infection (NHS).

How to prepare

Preparation is mostly paperwork and planning, and each item has a reason:

  • Gather your fertility results and scans. Earlier hormone tests, ultrasounds and tubal tests decide which medication and dose the clinic starts with, and abroad they let the clinic see your history without repeating everything.
  • List every medicine and supplement you take. The clinic reviews current medicines before choosing doses, and an incomplete list forces it to guess.
  • Plan the scan and stimulation timing. Oral treatment runs five days (Gloucestershire) and monitoring then continues through the following days of the cycle, so budget time off for scans and blood tests.
  • Arrange support and time. Several cycles are the norm, up to 6 (UHCW), and each one ends in a test that may be negative, so plan with whoever you share this with.
  • If you travel, get the clinic's written information. Your fertility clinic should provide full written information about your treatment, including the risk of OHSS and a 24-hour help number (RCOG).

Writing your questions down before the consultation helps you remember them. You can say these exact words:

  • "Which medication would you use for my cause, and why that one?"
  • "What is my realistic chance of conceiving each cycle, and how many cycles are tried before moving to another treatment?"
  • "How will my scans and blood tests be arranged, and who treats me if I develop OHSS while I am abroad?"
  • "What does your written aftercare plan cover once I fly home?"

What to expect, risks and recovery

The benefit is straightforward: a pregnancy that would not have happened. Clomiphene causes ovulation in 80% of women treated, about eight in ten, and about half of those who ovulate go on to achieve a pregnancy or live birth (NICHD). Across oral treatment generally, around 70 in every 100 patients ovulate and 40 in every 100 conceive (Gloucestershire). Once a woman is diagnosed with infertility, the overall likelihood of successful treatment is 50% (NICHD).

Cycles that do not succeed are hard to take, and going through several of them is draining; some couples ask the clinic how many cycles are worth planning before moving on.

The risks of treatment, and the risks of waiting

The downsides of the medication are real but mostly manageable. Fertility medicines can cause side effects such as nausea, vomiting, headaches and hot flushes (NHS). With clomiphene specifically, side effects are not common and tend to be dose related, with most people tolerating the medication well (Gloucestershire).

The one outcome nobody wants is unintended. Clomiphene increases the risk of having a multiple pregnancy: there is a 10% chance of twins, and triplets or more occur in less than 1% of cases (NICHD). Twins can result in up to 10% of cases with clomiphene treatment and 20% with gonadotropins, and triplets may occur in around 1% of cases (UHCW). With gonadotropins, 30% of women who conceive have multiple births (NICHD). Most gonadotropin births are still single babies, about 80%, and of the multiples the majority are twins, but neither single nor multiple births can be guaranteed (Health Canada). Multiples complicate pregnancy and birth more than single babies do (NICHD).

OHSS is a problem sometimes seen in women who take fertility medicines that stimulate egg production (MedlinePlus). It rarely occurs in women who only take fertility medicines by mouth, but is more likely after an hCG trigger or if you become pregnant (MedlinePlus). Mild OHSS is common in IVF treatment, affecting as many as 33 in 100 women, while just over 1 in 100 develops moderate or severe OHSS (RCOG). Severe OHSS can cause rapid weight gain of more than 10 pounds (4.5 kilograms) in 3 to 5 days, severe pain or swelling in the belly, decreased urination, shortness of breath, vomiting and blood clots (MedlinePlus). It can cause fluid build-up in the abdominal and chest areas and can cause blood clots to form (Health Canada). Call for medical help if the symptoms are not getting any better, or if you start to vomit, have urinary problems, chest pain or difficulty breathing (RCOG). Most symptoms should resolve in 7 to 10 days (RCOG). If you develop OHSS, your ovaries will be enlarged and painful, and you should avoid having sex or doing strenuous exercise to avoid injury to the ovaries (RCOG). A serious but rare complication is a blood clot in the legs or lungs, whose signs are a swollen, tender leg or chest pain with breathlessness (RCOG); the same clot warning signs, pain, swelling or warmth in a leg with shortness of breath or chest pain, need immediate help (Cleveland Clinic).

Gonadotropins also cause injection-site reactions, pain, redness, bruising or swelling where the needle goes (Health Canada). Ovarian enlargement with bloating and pain occurs in about 20% of women taking gonadotropins; it generally reverses with cessation of treatment, and severe life-threatening cases are rare (Health Canada).

An ectopic pregnancy, one that implants in a fallopian tube, is much more common after infertility treatment than after spontaneous pregnancy, and higher still among pregnancies resulting from ovulation induction, especially with clomiphene (Journal of Human Reproductive Sciences). A pregnancy after OI should be confirmed early by scan to be in the uterus (Health Canada).

Success per cycle is never guaranteed; if clomiphene does not bring pregnancy after six menstrual cycles, other fertility treatments are considered (NICHD).

The other side is what waiting does. Anovulation does not fix itself, PCOS has no cure and women with it do not ovulate regularly (ACOG). Unmanaged anovulation carries the endometrial and metabolic risks described earlier (NICHD). Age keeps moving, which is why specialist referral starts at 36 (NICE). The balance is not all alarm, though: most couples under 40 conceive within a year, and many more in the second (NHS). Not treating is a legitimate option; deciding after an assessment is a calmer version of the same choice.

Recovery after an uncomplicated cycle is quick; ovarian enlargement generally reverses when treatment stops (Health Canada), and mild OHSS usually passes without treatment (MedlinePlus). Flying after a cycle has no single agreed interval in the sources, so ask your clinic when you should fly, and never travel with any of the symptoms listed at the start of this page.

Finding ovulation-induction care abroad on MTR

People take OI abroad for cost, privacy, or waiting lists. A medication cycle abroad is shorter than a surgery trip, but the monitoring is the care, and it must be arranged wherever you are.

  • Read success claims by cycle, age and cause. Average chances may not reflect actual success rates during treatment for an individual or couple (CDC). Ask how many cycles a quoted rate covers and what ages it describes.
  • Confirm monitoring access. Scans and blood tests must be arranged before you start (UHCW, NICHD).
  • Get the written aftercare plan. Your fertility clinic should provide full written information about your treatment, including the risk of OHSS and a 24-hour help number (RCOG).
  • Know who handles an OHSS or a multiple pregnancy back home, and who pays. If you develop OHSS or a multiple pregnancy after you return, your home hospital handles it; check before you travel who treats you and whether your insurance covers emergency care and medical evacuation.
  • Flying while on stimulation. There is no fixed interval in the sources, so ask first, and never travel with any OHSS or clot symptom (RCOG, MedlinePlus).
  • Records. Get your scan and hormone results in English so a doctor at home can read them.

To compare providers offering ovulation induction, see the ovulation induction providers on MTR, and if you are still choosing a destination, start with our guide to top medical tourism destinations worldwide.

This week, book a fertility assessment if you have not been assessed, gather your prior results, and write down your questions.

Medical disclaimer: This information is for general educational purposes and is not medical advice. Always consult a qualified healthcare professional about your individual situation.

Reviewed against authoritative medical sources (Gloucestershire Hospitals NHS Foundation Trust; University Hospitals Coventry and Warwickshire NHS Foundation Trust; NHS England; NICE, the National Institute for Health and Care Excellence; NICHD, the National Institute of Child Health and Human Development, NIH; MedlinePlus, the US National Library of Medicine; the US Centers for Disease Control and Prevention; Health Canada; the Royal College of Obstetricians and Gynaecologists; the American College of Obstetricians and Gynecologists; Cleveland Clinic; the Journal of Human Reproductive Sciences).

Last reviewed: 20 November 2026

Providers that provide Ovulation Induction (oi) Service

Providers Score Reviews Location
Gryshchenko Clinic - IVF (GC-IVF)  
94.31
8 Ukraine
ISIDA-IVF Clinic
92.65
14 Ukraine
Op. Dr. Nezih Durmazlar
87.16
2 Turkey
Ovoclinic
60.17
1 Spain
Health and Beauty Turkey
Not Rated
0 Turkey
Hegde Fertility Centre
Not Rated
0 India
Indraprastha Apollo Hospitals Delhi
Not Rated
0 India
Medicana Ivf Center Istanbul
Not Rated
0 Turkey
Next Generation Clinic Moscow
Not Rated
0 Russia
Safe Fertility & Pgd Center
Not Rated
0 Thailand, United States
Sofat Hospital
Not Rated
0 India
Cairo Fertility Clinic
Not Rated
1 Egypt
Abington Memorial Hospital
Not Rated
0 United States
Adam International Hospital
Not Rated
0 Egypt
Advanced Fertility Services
Not Rated
0 United States
Advanced Reproductive Center Of Hawaii
Not Rated
0 United States
Altravita
Not Rated
0 Russia
Amarjeet Fertility Centre
Not Rated
0 India
Amrita Institute Of Medical Sciences
Not Rated
0 India
Armc Ivf Fertility Centre
Not Rated
0 India